Critical Reviews in Oncology / Hematology
Volume 78, Issue 3 , Pages 243-251 , June 2011

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status

  • Lorenzo Fornaro

      Affiliations

    • U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 67 - 56126 Pisa, Italy
    • ,
  • Giacomo Giulio Baldi

      Affiliations

    • U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 67 - 56126 Pisa, Italy
    • ,
  • Gianluca Masi

      Affiliations

    • U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 67 - 56126 Pisa, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 050 992451; fax: +39 050 992069.
    • ,
  • Giacomo Allegrini

      Affiliations

    • U.O. Oncologia Medica, Ospedale F. Lotti, Pontedera, Italy
    • ,
  • Fotios Loupakis

      Affiliations

    • U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 67 - 56126 Pisa, Italy
    • ,
  • Enrico Vasile

      Affiliations

    • U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 67 - 56126 Pisa, Italy
    • ,
  • Samanta Cupini

      Affiliations

    • U.O. Oncologia Medica, Azienda USL6 di Livorno, Livorno, Italy
    • ,
  • Irene Stasi

      Affiliations

    • U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 67 - 56126 Pisa, Italy
    • ,
  • Lisa Salvatore

      Affiliations

    • U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 67 - 56126 Pisa, Italy
    • ,
  • Chiara Cremolini

      Affiliations

    • U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 67 - 56126 Pisa, Italy
    • ,
  • Bruno Vincenzi

      Affiliations

    • U.O. Oncologia Medica, Università Campus Bio-Medico, Roma, Italy
    • ,
  • Daniele Santini

      Affiliations

    • U.O. Oncologia Medica, Università Campus Bio-Medico, Roma, Italy
    • ,
  • Giuseppe Tonini

      Affiliations

    • U.O. Oncologia Medica, Università Campus Bio-Medico, Roma, Italy
    • ,
  • Francesco Graziano

      Affiliations

    • U.O. Oncologia Medica, Ospedale di Pesaro, Pesaro, Italy
    • ,
  • Annamaria Ruzzo

      Affiliations

    • Dipartimento di Scienze Biomolecolari, Università di Urbino, Urbino, Italy
    • ,
  • Emanuele Canestrari

      Affiliations

    • Dipartimento di Scienze Biomolecolari, Università di Urbino, Urbino, Italy
    • ,
  • Mauro Magnani

      Affiliations

    • Dipartimento di Scienze Biomolecolari, Università di Urbino, Urbino, Italy
    • ,
  • Alfredo Falcone

      Affiliations

    • U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 67 - 56126 Pisa, Italy

,Accepted 10 June 2010.

References 

  1. Merlin F, Prochilo T, Tondulli L, et al. Colorectal cancer treatment in elderly patients: an update on recent clinical studies. Clin Colorectal Cancer. 2008;7:357–363
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  3. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–2067
  4. McKibbin T, Frei CR, Greene RE, et al. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist. 2008;13:876–885
  5. Raftery L, Sanoff HK, Goldberg R. Colon cancer in older adults. Semin Oncol. 2008;35:561–568
  6. Papamichael D, Audisio R, Horiot JC, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol. 2009;20:5–16
  7. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to ECOG performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20:494–502
  8. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how?. Br J Cancer. 2009;100:1704–1719
  9. Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist. 2009;14:478–488
  10. Kabbinavar FF, Hurwitz HI, Yi J, et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2008;27:199–205
  11. Kozloff MF, Sugrue MM, Purdie DM, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study. J Clin Oncol. 2008;26(May 20 Suppl.):abs 4026
  12. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of bevacizumab (BEV) and chemotherapy in elderly patients with metastatic colorectal cancer (mCRC): results from the BEAT observational cohort study. Eur J Cancer Suppl. 2009;7(2):abs 6088
  13. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory colorectal cancer. N Engl J Med. 2004;351:337–345
  14. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–2048
  15. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311–2319
  16. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663–671
  17. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–1417
  18. Bouchahada M, Macarulla T, Spano JP, et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008;67:255–262
  19. Sastre J, Aranda E, Grávalos C, et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol. 2009;(December):[Epub ahead of print]. doi:10.1016/j.critrevonc.2009.11.005.
  20. Rivera F, Gravalos C, Massuti B, et al. Cetuximab and capecitabine as first line treatment for elderly patients with metastatic colorectal cancer: preliminary results of TTD trial. Eur J Cancer Suppl. 2009;7(2):abs 4004
  21. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995
  22. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765
  23. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–1634
  24. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705–5712
  25. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101:715–721
  26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. EORTC, NCI USA, NCI Canada. J Natl Cancer Inst. 2000;92:205–216
  27. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009;27:2622–2629
  28. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. 2010 Gastrointestinal Cancers Symposium, abs 281.
  29. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: updated data from the OPUS study. 2010 Gastrointestinal Cancers Symposium, abs 428.

PII: S1040-8428(10)00143-5

doi: 10.1016/j.critrevonc.2010.06.003

Critical Reviews in Oncology / Hematology
Volume 78, Issue 3 , Pages 243-251 , June 2011

Article Tools

* Image Usage & Resolution